Inflammation and mixed lung damage after tuberculosis treatment

Post-tuberculosis lung disease is a common but poorly understood consequence for people who have completed treatment for pulmonary tuberculosis. To explore what drives this condition, Stephanus T. Malherbe and collaborators conducted an exploratory study of 48 adults who had finished TB treatment within the prior six months. The research team set out to link what can be seen on the body’s scans with how people feel and how their immune systems behave. To do this they used extensive clinical phenotyping: fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)-computed tomography (CT) scans to map inflammation and anatomy, pulmonary function testing to measure breathing capacity, and symptom and quality of life questionnaires to capture how patients were doing day to day. They also looked directly at immune cells from blood and bronchoalveolar lavage fluid (BALF) to understand local and systemic immune activity. The overall aim was to examine immune, metabolic, anatomical, and functional features together, rather than in isolation, to build a clearer picture of the changes that persist after successful TB treatment.

The study combined imaging, physiological tests, and laboratory immune measures to search for links. Imaging measures included PET metrics such as total glycolytic activity and SUVmax, and CT measures such as the number of segments involved. Pulmonary function testing provided measures of airflow and lung volumes, and exercise tolerance and symptom scores were recorded from questionnaires. Immunological profiling was performed on paired blood- and bronchoalveolar lavage fluid-derived immune cells using multiplex bead-based immunoassay, ELISA and flow cytometry. The researchers found agreement between PET measures of inflammation, the severity of anatomical abnormalities on CT, and results from pulmonary function testing, indicating these different measures reflect related aspects of lung damage. Notably, only PET inflammation measures were associated with exercise tolerance and symptom scores. Radiologic extent on PET and CT correlated with blood-detected proteins that implicate Type 1 (IFN-γ, TNFα, IL-12) and Type 2 (IL-4, IL-33) immune responses, markers of ongoing tissue remodelling (MMPs), vascular and airway factors (VEGF), and subsets of activated CD8 + and CD4 + T-cells.

These results suggest that structural lung changes after tuberculosis are linked to a broad pattern of immune dysregulation and measurable loss of lung function. Rather than falling neatly into purely obstructive or purely restrictive categories, the findings indicate a mixed pathology in many TB survivors, with both airway obstruction and reduced lung volumes present. The association of PET-detected inflammation with symptoms and exercise tolerance highlights the potential value of metabolic imaging in identifying people whose residual disease is clinically important. The correlated blood proteins offer clues to the types of immune activity and tissue remodelling that persist after treatment and may serve as targets for future study or monitoring. Overall, the work points to the need for integrated assessment—combining imaging, lung function testing, and immune measures—to better identify, follow, and ultimately treat people with post-tuberculosis lung disease.